WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATCvet codes

New ATCvet codes 2021

 Updates included in the ATCvet Index valid from 2021.

ATC codeATCvet level name
QA03AX15menthae piperitae aetheroleum
QA05BA09metadoxine
QA06AX08tenapanor
QA10BD26metformin and lobeglitazone
QA10BG04lobeglitazone
QA10BH08teneligliptin
QA10BJ07beinaglutide
QA10BK07luseogliflozin
QA16AX16givosiran
QA16AX17triheptanoin
QA16AX18lumasiran
QA16AX30sodium benzoate and sodium phenylacetate
QB03AD05ferrous gluconate
QB05XA18zinc sulfate
QB06AX02betibeglogene autotemcel
QC01DX22vericiguat
QC09BX05ramipril and bisoprolol
QC10AX16inclisiran
QC10BA10bempedoic acid and ezetimibe
QC10BX18atorvastatin, amlodipine and ramipril
QD01BA03fosravuconazole
QD05AX55tazarotene and ulobetasol
QD06BX03tirbanibulin
QD10AF07minocycline
QD11AH07tralokinumab
QD11AX26caffeine
QG02CX05bremelanotide
QG03AA18drospirenone and estetrol
QH01AC07somapacitan
QH01CC54relugolix, estradiol and norethisterone
QH02CA03 1)ketoconazole
QH05AA04abaloparatide
QH05BX05 2)calcifediol
QI07AV01staphylococcus + bacteriophage
QJ01DH56imipenem, cilastatin and relebactam
QJ01DI04cefiderocol
QJ01MA24levonadifloxacin
QJ01MA25lascufloxacin
QJ04AK08pretomanid
QJ05AJ04cabotegravir
QJ05AX28bulevirtide
QJ05AX29fostemsavir
QL01EE04selumetinib
QL01EH03tucatinib
QL01EL03zanubrutinib
QL01EM04duvelisib
QL01EX15pexidartinib
QL01EX16erdafitinib
QL01EX17capmatinib
QL01EX18avapritinib
QL01EX19ripretinib
QL01EX20pemigatinib
QL01EX21tepotinib
QL01XC34moxetumomab pasudotox
QL01XC35tafasitamab
QL01XC36enfortumab vedotin
QL01XC37polatuzumab vedotin
QL01XC38isatuximab
QL01XC39belantamab mafodotin
QL01XC40dostarlimab
QL01XC41trastuzumab deruxtecan
QL01XK05veliparib
QL01XX69lurbinectedin
QL01XX70axicabtagene ciloleucel
QL01XX71tisagenlecleucel
QL01XY02pertuzumab and trastuzumab
QL04AA45filgotinib
QL04AA46itacitinib
QL04AA47inebilizumab
QL04AC19satralizumab
QM02AA29esflurbiprofen
QM09AX08golodirsen
QM09AX09onasemnogene abeparvovec
QM09AX10risdiplam
QM09AX11palovarotene
QN01BB59bupivacaine and meloxicam
QN02AA11oxymorphone
QN02BG11mirogabalin
QN03AX25cenobamate
QN03AX26fenfluramine
QN04CX01istradefylline
QN05CD15nimetazepam
QN05CM96tasipimidine
QR01AD59mometasone, combinations
QR07AX32ivacaftor, tezacaftor and elexacaftor
QS01GA07brimonidine
QS01LA07abicipar pegol
QV03AB96ropinirole
1) Oral formulations only indicated in treatment of Cushing’s
2) Oral formulations only indicated in treatment of renal secondary hyperparathyroidism

New ATC 3rd and 4th levels

QJ05AJIntegrase inhibitors
QL01CETopoisomerase 1 (TOP1) inhibitors
QL01EPROTEIN KINASE INHIBITORS
QL01EABCR-ABL tyrosine kinase inhibitors
QL01EBEpidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
QL01ECB-Raf serine-threonine kinase (BRAF) inhibitors
QL01EDAnaplastic lymphoma kinase (ALK) inhibitors
QL01EEMitogen-activated protein kinase (MEK) inhibitors
QL01EFCyclin-dependent kinase (CDK) inhibitors
QL01EGMammalian target of rapamycin (mTOR) kinase inhibitors
QL01EHHuman epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
QL01EJJanus-associated kinase (JAK) inhibitors
QL01EKVascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
QL01ELBruton's tyrosine kinase (BTK) inhibitors
QL01EMPhosphatidylinositol-3-kinase (Pi3K) inhibitors
QL01EXOther protein kinase inhibitors
QL01XFRetinoids for cancer treatment
QL01XGProteasome inhibitors
QL01XHHistone deacetylase (HDAC) inhibitors
QL01XJHedgehog pathway inhibitors
QL01XKPoly (ADP-ribose) polymerase (PARP) inhibitors
QN04COTHER ANTIPARKINSON DRUGS
QN04CXOther antiparkinson drugs

Last updated: 2021-01-26